Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Serotonin and Raynaud's phenomenon.

J R Seibold

    Journal of Cardiovascular Pharmacology
    |January 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Serotonin contributes to Raynaud's phenomenon by causing vasospasm, particularly in systemic sclerosis. Ketanserin, an S2-serotonergic receptor antagonist, improves digital artery flow and cold tolerance, suggesting antiplatelet therapies could benefit patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

    Clinical and experimental rheumatology·2013
    Same author

    Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.

    Arthritis and rheumatism·2012
    Same author

    Differences in presentation of younger and older systemic sclerosis patients in clinical trials.

    Clinical and experimental rheumatology·2010
    Same author

    Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

    Arthritis and rheumatism·2010
    Same author

    A world of progress in systemic sclerosis.

    Clinical and experimental rheumatology·2009
    Same author

    Sexual activity and functioning in female scleroderma patients.

    Clinical and experimental rheumatology·2009

    Area of Science:

    • Vascular Biology
    • Pharmacology
    • Rheumatology

    Background:

    • Cold-induced vasospasm in Raynaud's phenomenon lacks a single explanation.
    • Serotonin release from platelets contributes to vasospasm, especially in systemic sclerosis.
    • Platelet-derived growth factors and serotonin may promote fibrotic arteriosclerosis.

    Purpose of the Study:

    • To investigate the role of serotonin in different forms of Raynaud's phenomenon.
    • To evaluate the efficacy of ketanserin, an S2-serotonergic receptor antagonist, in managing Raynaud's symptoms.
    • To explore the potential benefits of antiplatelet therapies.

    Main Methods:

    • Selective antagonism of S2-serotonergic receptors with ketanserin.
    • Assessment of maximal digital artery flow and cold tolerance.

    Related Experiment Videos

  • Distinguishing between primary (spastic) Raynaud's and Raynaud's associated with systemic sclerosis.

    • Main Results:

    • Ketanserin improved digital artery flow and cold tolerance in Raynaud's patients.
    • In primary Raynaud's, ketanserin relieved but did not prevent cold-induced vasospasm.
    • Findings suggest serotonin's role in maintaining vasospasm, not provoking it, in primary Raynaud's.

    Conclusions:

    • Serotonin plays a role in Raynaud's phenomenon, particularly in systemic sclerosis.
    • Ketanserin demonstrates therapeutic potential by improving vascular function and cold tolerance.
    • Antiplatelet therapies may offer benefits for both primary and secondary Raynaud's phenomenon.